Biotech · Private company
BRIM Biotechnology Inc.
Track this companyFree. Adds BRIM Biotechnology Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- BRM421Phase 3 · Dry Eye SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- BRM421 Ophthalmic SolutionPhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VehiclePhase 3 · Dry Eye DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BRM424 Ophthalmic Solution - Dose1Phase 2 · Neurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
- BRM424 Ophthalmic Solution - Dose2Phase 2 · Neurotrophic KeratitisClinicalTrials.gov · fetched Nov 12, 2026
- BRM421 Ophthalmic Solution, 0.06%Limbal Stem Cell Deficiency (LSCD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic KeratitisPHASE2 · UNKNOWN · started Jul 31, 2024ClinicalTrials.gov NCT05927428 · fetched Nov 12, 2026
- Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.PHASE3 · COMPLETED · started Feb 27, 2023ClinicalTrials.gov NCT05695781 · fetched Nov 12, 2026
- Safety and Efficacy of BRM421 for Dry Eye Syndrome TreatmentPHASE2_PHASE3 · COMPLETED · started Jan 15, 2020ClinicalTrials.gov NCT04343287 · fetched Nov 12, 2026
- Safety and Efficacy of BRM421 for Dry Eye SyndromePHASE2 · COMPLETED · started Feb 7, 2017ClinicalTrials.gov NCT03066219 · fetched Nov 12, 2026
- BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell DeficiencyAVAILABLEClinicalTrials.gov NCT07422389 · fetched Nov 12, 2026